Disinvestment & Early Awareness Awareness
Interest Group — ALERTS

Introduction
Welcome to the second alert - a collaborative effort by HTAi, the Norwegian Institute of Public Health, and CADTH to provide updates on new studies relevant to disinvestment, reassessment, early awareness and horizon scanning. Alerts are issued quarterly and members of the Disinvestment & Early Awareness Interest Group will receive an email notification when new issues are posted on the HTAi web site.

The intent of these alerts is not to identify specific technologies for disinvestment or early assessment, but rather to select papers on methods and issues, and broader forecasts of technologies that may be of interest. A second aim of the project is to reduce duplication of effort by providing current awareness that we hope will be relevant for many HTA agencies.

The references in this Alert are selected from search results (for both disinvestment and for horizon scanning) from PubMed and Google, as well as additional references we come across in the course of our regular work. The publications for this second issue were selected from a search covering publications identified in the period June to August 2019. The search strategies were drafted and peer reviewed by the Information Specialists for this pilot project and the search strategies are available upon request.

Where the full publication is freely available the title is hyperlinked. The PubMed (PM) id is hyperlinked to the abstract in PubMed.

Disinvestment


Guay M, Ruest M, Contandriopoulos D. Deimplementing untested practices in homecare services: a preobservational-postobservational design. Occup Ther
Horizon Scanning


Books & Reports

Emerging biopharma's contribution to innovation: assessing the impact. IQVIA Institute Report, June 4, 2019. *Access to full report requires free registration


Patient-Centered Outcomes Research Institute (PCORI); 2019 Jun.

MEDS pipeline monitor 2018. Ottawa: Patented Medicine Prices Review Board, 2019. *A horizon scanning report on new drugs in late stages of development (including orphan drugs, oncology drugs, and biologics), that may have a significant impact on clinical practice and health care costs in Canada.

Monthly horizon scanning reports. UK NHS, Regional Drug & Therapeutics Centre (RDTC). *These describe new UK drug products, and new drug and non-drug guidance from NICE and other UK agencies.


We welcome your comments on this alert and suggestions of publications to include in the next issue. Please send them to Leigh-Ann Topfer, CADTH, email: leigh-annt@cadth.ca

Contributors: This Alert is a collaborative effort by the HTAi Disinvestment & Early Awareness Interest Group and the HTAi Information Retrieval Interest Group:

- Rosmin Esmail (Alberta Health Services) – Chair, HTAi Disinvestment & Early Awareness Interest Group
- Dr. Julie Polisena (CADTH) – Past Chair, HTAi Disinvestment & Early Awareness Interest Group
- Dr. Vigdis Lauvrak (Norwegian Institute of Public Health) – Past Co-Chair, HTAi Disinvestment & Early Awareness Interest Group
- Anna Lien Espeland (Norwegian Institute of Public Health) – Technical Officer, HTAi Disinvestment & Early Awareness Interest Group
- Kelly Farrah (CADTH) – Information Specialist
- Ingrid Harboe (Norwegian Institute of Public Health) – Chair-Elect, HTAi Information Retrieval Interest Group
- Elisabet Hafstad (Norwegian Institute of Public Health) – Information Specialist
- Amanda Hodgson (CADTH) – Information Specialist
- Dr. Ingrid Kristine Ohm (Norwegian Institute of Public Health)
- Leigh-Ann Topfer (CADTH)